Clinical trial · Observational
Tissue Collection for Biomarkers Determining Resistance to Ibrutinib
Clinical Validation of Biomarkers Determining Resistance to BTK Inhibition With Ibrutinib in Mantle Cell Lymphoma & Chronic Lymphocytic Leukaemia - Stage 1
NCT02267590CI-TRIAL-00015858CLARITYunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Clinical validation of biomarkers determining resistance to BTK inhibition with Ibrutinib in Mantle Cell Lymphoma and Chronic Lymphocytic Leukaemia Stage 1.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Lymphocytic Leukaemia | Chronic Lymphocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
| Mantle Cell Lymphoma | Mantle Cell Lymphoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- MCL: 80-100 samples from 60- 70 patients
- description
- Mantle Cell lymphoma patients
- label
- CLL: 15-20 samples from 10-15 patients
- description
- Chronic lymphocytic leukaemia patients
Primary outcomes (1)
- measure
- Total number of MCL and CLL patient samples collected, both pre-treatment and at progression.
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * All patients entered into the Ibrutinib NPS for relapsed refractory MCL and CLL in the UK and who consent to have biological material stored for this research will be included in the study. Patients who have already commenced treatment with Ibrutinib will also be eligible whether or not they are responding. Exclusion Criteria: * All samples received will undergo histological (or morphological) review and immunophenotyping. The following samples will be excluded- 1. Samples not satisfying the criteria for diagnosis of CLL or MCL. 2. Samples with evidence of high grade transformation (e.g. Richter's transformation of CLL).
References
Publications (0)
Data not yet available
No reference posted for this study.